As­traZeneca, Sanofi turn to Al­pha­bet spin­out's AI and quan­tum tech­nolo­gies for drug dis­cov­ery

As part of its bio­phar­ma R&D ac­cel­er­a­tion ef­forts, an Al­pha­bet spin­out an­nounced to­day that it’s work­ing with As­traZeneca, Sanofi and oth­ers on drug dis­cov­ery and sim­u­la­tion projects.

Sanofi and As­traZeneca plan to use Sand­box­AQ’s sim­u­la­tion, AI and oth­er quan­tum tech­nolo­gies to gain an edge on their com­peti­tors and de­vel­op drugs more quick­ly. Sand­box­AQ cur­rent­ly fo­cus­es on mol­e­c­u­lar sim­u­la­tion, which it says en­tails

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER